Home Cart Sign in  
Chemical Structure| 479413-70-2 Chemical Structure| 479413-70-2

Structure of AUDA
CAS No.: 479413-70-2

Chemical Structure| 479413-70-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AUDA is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively and with anti-inflammatory activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AUDA

CAS No. :479413-70-2
Formula : C23H40N2O3
M.W : 392.58
SMILES Code : O=C(O)CCCCCCCCCCCNC(NC12CC3CC(C2)CC(C3)C1)=O
MDL No. :MFCD12912267
InChI Key :XLGSEOAVLVTJDH-UHFFFAOYSA-N
Pubchem ID :10069117

Safety of AUDA

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P264-P270-P301+P312-P330-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
prefrontal cortex neurons 1 μM, 5 μM, 10 μM 10 min To evaluate the effect of AUDA on excitatory synaptic transmission in prefrontal cortex neurons. Results showed that AUDA significantly increased the amplitude of EPSCs and fEPSPs, indicating enhanced excitatory synaptic transmission. J Biomed Sci. 2015 Oct 22;22:94
3T3-L1 preadipocytes 1 µM 12 h To evaluate the effect of EETs combined with AUDA on PPARγ target gene expression. Results showed that EETs combined with AUDA increased the mRNA level of adipocyte P2. Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16747-52
Human umbilical vein endothelial cells (HUVECs) 1 µM 12 h To evaluate the effect of EETs combined with AUDA on PPARγ target gene expression. Results showed that EETs combined with AUDA increased the mRNA level of fatty acid-binding protein 4. Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16747-52
Bovine aortic endothelial cells (BAECs) 1 µM 8 h To evaluate the effect of EETs combined with AUDA on PPARγ transcriptional activity. Results showed that EETs significantly increased PPARγ transcriptional activity in the presence of AUDA. Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16747-52
Rat VSMCs 0.3 to 30 µg/mL 24 h To evaluate the effect of AUDA on HO-1 and Keap1 expression. AUDA dose-dependently reduced Keap1 levels and increased HO-1 protein levels. Int J Mol Sci. 2017 Dec 11;18(12):2683
Rat VSMCs 0.3 to 10 µg/mL 48 h To evaluate the effect of AUDA on PDGF-induced proliferation of rat VSMCs. AUDA significantly inhibited PDGF-induced rat VSMC proliferation. Int J Mol Sci. 2017 Dec 11;18(12):2683

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Male Sprague-Dawley rats Angiotensin-dependent hypertensive model Oral 25 mg/L 14 days Lower blood pressure and ameliorate renal damage Hypertension. 2005 Oct;46(4):975-81
Goto-Kakizaki rats Hypertension and type II diabetes model Drinking water 25 mg/L 14 days AUDA treatment reduced renal damage in hypertensive Goto-Kakizaki rats, decreased urinary albumin excretion and monocyte/macrophage infiltration, and inhibited MCP-1 gene expression and urinary excretion. Clin Sci (Lond). 2009 Jan;116(1):61-70
Rats Spontaneously hypertensive stroke-prone (SHRSP) rats and normotensive Wistar-Kyoto (WKY) rats Drinking water 2 mg/day Daily administration for 6 weeks To investigate the protective effects of AUDA against cerebral ischemia in normotension and hypertension. Results showed that AUDA reduced hemispheric infarct size and neurodeficit score in SHRSP rats via vascular and neural protection, while in WKY rats, it primarily provided neural protection. Am J Pathol. 2009 Jun;174(6):2086-95
C57Bl/6 mice Middle cerebral artery occlusion (MCAO) model Intraperitoneal injection 10 mg/kg Single injection, lasting 24 hours To evaluate the protective effect of AUDA-BE on ischemic brain injury, results showed that AUDA-BE significantly reduced infarct size J Cereb Blood Flow Metab. 2007 Dec;27(12):1931-40

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.55mL

0.51mL

0.25mL

12.74mL

2.55mL

1.27mL

25.47mL

5.09mL

2.55mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories